ICAM1 and neoplasm: Notably, a recent study revealed that activation of EpCAM-specific CAR-T cells can lead to compensatory upregulation of ICAM - 1 on tumor cells, thereby increasing their susceptibility to dual-targeted CAR-T cells against both EpCAM and ICAM - 1.